HRZE Does Not Directly Worsen Psoriasis
The standard HRZE tuberculosis regimen (isoniazid, rifampin, pyrazinamide, ethambutol) does not inherently worsen psoriasis and should be used when tuberculosis treatment is indicated. In fact, emerging evidence suggests that treating tuberculosis infection may actually improve psoriasis in some cases.
Key Clinical Considerations
Evidence for Improvement, Not Worsening
Paradoxically, treating tuberculosis infection with isoniazid has been associated with significant improvement or even remission of severe psoriasis 1. Two case reports documented patients with extensive psoriasis who experienced dramatic clearing of skin lesions after receiving isoniazid 300 mg/day for latent TB treatment, without any other concurrent psoriasis therapy. This suggests a potential pathogenic link between mycobacterial infection and psoriasis activity.
The Real Clinical Challenge: Stopping Immunosuppression
The actual risk to psoriasis patients occurs when immunosuppressive therapy is abruptly discontinued upon TB diagnosis, not from the HRZE regimen itself 2. When systemic immunosuppression for psoriasis is suddenly stopped due to TB disease, severe psoriasis flares commonly occur. These flares are frequently misinterpreted as drug reactions to TB medications, leading to dangerous treatment interruptions and potential drug resistance.
Practical Management Algorithm
When TB is diagnosed in a psoriasis patient on immunosuppression:
- Do NOT abruptly stop all psoriasis therapy - this triggers severe flares that mimic drug reactions
- Initiate standard HRZE therapy as recommended 3, 4, 5, 6:
- 2 months: Isoniazid, Rifampin, Pyrazinamide, Ethambutol
- 4 months: Isoniazid, Rifampin
- Coordinate with dermatology to transition psoriasis management to non-biologic agents (acitretin, cyclosporine with planned taper, topicals) 2
- Monitor skin changes carefully - distinguish psoriasis flare from true drug reaction through collaborative assessment
Important Caveats
- Methotrexate increases TB risk (HR 2.16) and should be discontinued 7
- Tacrolimus significantly increases TB risk (HR 5.31) 7
- Systemic steroids increase TB risk in dose-dependent fashion (HR 1.09 per mg prednisolone equivalent) 7
- Patients with severe psoriasis may have decreased TB-specific immune responses, potentially leading to false-negative tuberculin skin tests 8
The Bottom Line
Proceed with standard HRZE therapy without hesitation. The tuberculosis itself poses far greater morbidity and mortality risk than any theoretical worsening of psoriasis. The evidence actually suggests TB treatment may improve psoriasis. The key is maintaining some level of psoriasis control with non-biologic agents during TB treatment to prevent flares that complicate management. A collaborative approach between TB specialists and dermatology is essential 2.